Higher Uric Acid Serum Levels Are Associated With Sarcopenia In West China: Results From The WCHAT Study

Xiaolei Liu  
National Clinical Research Center for Geriatrics

Xiaoyan Chen  
Zigong Mental Health Center

Fengjuan Hu  
National Clinical Research Center for Geriatrics

Lisha Hou  
National Clinical Research Center for Geriatrics

Xin Xia  
National Clinical Research Center for Geriatrics

Shuyue Luo  
National Clinical Research Center for Geriatrics

Gongchang Zhang  
National Clinical Research Center for Geriatrics

Xuchao Peng  
National Clinical Research Center for Geriatrics

Xulian Sun  
National Clinical Research Center for Geriatrics

Jirong Yue  
National Clinical Research Center for Geriatrics

Birong Dong (birongdong@163.com)  
National Clinical Research Center for Geriatrics

Research Article

Keywords: Uric acid (UA), handgrip strength (HGS), SMI, sarcopenia

Posted Date: September 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-476203/v1
Abstract

**Background:** Sarcopenia is the decline in muscle strength and mass attributed to aging. The pathogenesis of sarcopenia may be triggered by oxidative stress and uric acid (UA) has strong antioxidant properties. The aim of this study was to investigate the relationship between UA and sarcopenia in community-dwelling adults of West China using the baseline data of West China Health and Aging Trend (WCHAT) study.

**Methods:** 4236 adults aged 50 years or older in communities of west China were enrolled in this study. We applied AWGS 2019 criteria to define sarcopenia. Muscle mass was measured using skeletal muscle index (SMI) based on bioimpedance analysis (BIA). Handgrip strength (HGS) and gait speed (GS) were recorded, respectively. Different variables like anthropometry measures, life styles, chronic disease and blood test were collected.

**Results:** Participants were grouped according to UA quartiles by gender. After adjusting for potential confounders, a significant association between serum UA levels and sarcopenia was shown both in men and women. And a significant association between serum UA levels and HGS in women was shown as a inverted J shape. Besides, the association between the UA quartiles and SMI was significant, irrespective of gender.

**Conclusions:** Our results showed that a specific range of serum UA levels might be associated with sarcopenia and better HGS or SMI among Chinese adults aged over 50. Higher UA serum levels might slow down the progression of sarcopenia.

Introduction

Sarcopenia was an age-dependent loss of muscle mass and function which was common among older adults, leading to disability, loss of independence and death\(^1\). The prevalence of sarcopenia varies in different countries according to different diagnostic criteria. In west China, our previous studies showed a high prevalence of sarcopenia which was 19.31% in 4500 participants over 50 years old\(^2\). According to recent studies, sarcopenia was significantly associated with ethnicity, age, gender, obesity, life styles, chronic disease and so on\(^3\). In addition to these risk factors, age-related decreases in hormone concentrations could cause loss of muscle mass and strength, such as growth hormone, testosterone, thyroid hormone, vitamin D, albumin and insulin-like growth factor\(^4\). Another metabolic factor, uric acid (UA), was studied most recently in the relationship with skeletal muscle mass and/or strength, but the conclusions were varied and ambiguous\(^5,6\).

As the final product of purine metabolism, UA is generated in the xanthine/hypoxanthine reactions and other potentially deleterious prooxidant molecules are produced as a by-product of this reaction. As a result of this, UA has been treated as a reliable marker of oxidative stress\(^7\). UA is a crucial endogenous antioxidant, which can eliminate reactive oxygen species (ROS) and, thus preventing oxidative stress.
Recently, it was found that UA was positively associated with muscle mass and strength in kidney transplant patients\(^6\). Besides, another cross-sectional study showed that a specific range of serum UA levels may be associated with better hand grip strength among Chinese adults aged over 45\(^5\). However, in a study of 586 Japanese men aged over 30, it was found that hyperuricemia was associated with reduced muscle strength, and UA levels showed an inverted J-shaped curve with handgrip strength\(^8\). What's more, in a sample of 7,544 US men and women aged 40 and above, it showed that increased serum UA was significantly related with sarcopenia after adjustment for the cofounders\(^9\).

In our study, we grouped the participants according to UA quartiles by gender. Then we performed our study to determine the relationship between sarcopenia and UA in a large group of multi-ethnic residents enrolled in the West-China Health and Aging Trend Study (WCHAT). Specifically, we also investigated the relationship between UA and skeletal muscle index (SMI), grip strength (HGS) and gait speed (GS).

### Materials And Methods

#### Study Sample

The current research is a cross-sectional analysis obtaining baseline data of the WCHAT study between July 2018 and October 2018\(^10\). Participants aged \(\geq\) 50 years were selected from 4 provinces including Yunnan, Guizhou, Sichuan, and Xinjiang. Participants were recruited by convenience and asked verbally by the researchers about their willingness to take part in the study. Before investigation, informed consent was signed and obtained by each participant. Initially, we recruited 7536 community-dwelling multi-ethnic residents in total. 4500 participants did the bioelectrical impedance analysis (BIA) which is available for the selection of sarcopenia. Then other small ethnic group participants (n=67), participants without blood uric acid test (n=57), participants with kidney disease (n=87), participants with mental disease (n=5) and participants with tumor (n=24) were excluded. Finally, 4260 participants were included and were grouped according to UA quartiles in our study (Figure 1).

#### Definitions of Sarcopenia

We defined sarcopenia according to the AWGS 2019\(^11,12\) which defined sarcopenia according to low skeletal muscle mass, low strength, and/or low physical function. Skeletal muscle mass was estimated by a trained doctor using a bioimpedance analysis (BIA) device (InBody 770, Biospace, Korea). For AWGS 2019, the SMI was using BIA predicted skeletal muscle mass and cutoffs were 7.0 kg/m\(^2\) in men and 5.7 kg/m\(^2\) in women. Grip strength was measured using a dynamometer (EH101; Camry, Zhongshan, China) to test the muscle strength. Tests were performed on two independent occasions using the dominant hand and the largest value was recorded. Cutoffs of grip strength was defined as 28kg in men and 18kg in women. The physical function was estimated using gait speed (GS) through a 4-m walking test. The walking time was recorded using a kind of infrared sensor and the acceleration phase was strictly excluded. The participants were asked to perform the test by walking at a normal pace. Subjects stood at the starting point and upon the starting command, walked forward at a normal pace to the 4-meter line.
During the test, subjects wore common shoes, could use mobility aids, but could not be assisted. There were no time limits to the assessments and subjects could stop and rest if necessary. Sitting down was prohibited. The participants performed 2 trials, and the results were averaged to the nearest 0.01 m/s. The cutoff of gait speed was defined as less than 1.0m/s.

**Demographic data and blood sample collection**

Information regarding age, gender, ethnic groups, education level, smoking history and alcohol consumption history was gathered. Blood samples were drawn from the vein in the morning after a minimum of 8 h of fasting. Blood handling and collection was carried out under strictly standardized conditions. UA level were measured using the same standard.

**Assessment of cognition, depression, sleep quality and chronic diseases**

Cognitive status was assessed using a 10-item Short Portable Mental Status Questionnaire (SPMSQ)\(^{13}\) and the result was based on educational level. Depressive symptoms were assessed using the 15-item Geriatric Depression Scale (GDS-15)\(^{14}\). Sleeping quality was assessed using the Pittsburgh Sleep Index Scale (PSQI) questionnaire\(^{15}\). A medical history of chronic disease was self-reported. These disease conditions included hypertension, diabetes mellitus, coronary heart disease (CHD), liver disease, chronic obstructive pulmonary disease (COPD), gastrointestinal disease, stroke and osteoarticular disease.

**Statistical Analyses**

The data analyses were performed using SPSS version 20.0 (SPSS Inc, Chicago, IL). The categorical data was presented as counts (percentages), and the normal distributed continuous data was presented as mean (standard deviation [SD]). For the normal distribution variables, the difference between the groups is compared by the independent sample T-test and the count data is compared using the \(\chi^2\) test. Participants was grouped according to UA quartiles. We also performed UA subgroup analyses according to gender. The relationship between UA and sarcopenia was estimated by deriving odds ratios (ORs) and 95% confidence intervals (CIs) from multivariate logistic regression models. We also performed multivariate logistic regression models to investigated the three components and A value of \(P\leq0.05\) (two-side) was considered to be statistically significant.

**Results**

**Characteristics of Participants**

We included 4260 participants (1542 men and 2718 women). Participants was grouped according to quartiles of UA (Q1, \(<269.825\text{umol/L}\); Q2, 269.825 ~318.15\text{umol/L}; Q3, 318.15 ~378.75\text{umol/L}; Q4, \(\geq378.75\text{umol/L}\)). Table 1 shows the association of UA tertiles with participants' characteristics in the whole sample. The higher of the UA level, the higher mean age of the participants and the lower percentage of female. Besides, the higher of the UA level, the higher percentage of drinking and smoking.
The GDS score of the participants in the Q4 group was significantly lower than the Q1 group and the percentage of cognitive decline in the Q4 group was significantly lower than the Q1 group. However, the percentage of hypertension, diabetes and CHD was significantly higher in the Q4 group than the Q1 group.

*Serum UA level and sarcopenia*

Table 2 showed the relationship between UA tertiles and sarcopenia in non-adjusted model and adjusted model in female and male, respectively. We grouped UA levels according to gender: In female, Q1 <253.85umol/l, 253.85≤Q2<293.8umol/l, 293.8≤Q3<340.4umol/l, 340.4umol/l≤Q4; In male, Q1* <319.2umol/l, 319.2≤Q2<372.25umol/l, 372.25≤Q3<423.525umol/l, 423.525umol/l≤Q4*. In non-adjusted model, sarcopenia was mostly significantly associated with UA in both male and female. In adjusted model which adjusted age, ethnic groups, GDS score, sleeping quality, education level, cognitive function, smoking history, drinking history, ADL score, and chronic disease (hypertension, diabetes, coronary heart disease, chronic obstructive pulmonary disease, osteoarthropathy, liver disease, gastrointestinal disease, stroke history), sarcopenia was still significantly associated with Q3* (OR 0.664, 95% CI 0.462-0.955) and Q4* (OR 0.513, 95%CI 0.349-0.753) group in male. Besides, in adjusted model, sarcopenia was significantly associated with UA in female with a dosage effect (Q2#, OR 0.729, 95% CI 0.542-0.982; Q3#, OR 0.593, 95% CI 0.436-0.805; Q4#, OR 0.477, 95% CI 0.348-0.652).

*Serum UA level and SMI/GS/HGS*

The results of general linear models for the relationship between UA levels and SMI/GS/HGS in male and female were presented in table 3. We found that serum UA level was independently associated with SMI in female with a dosage effect [Q2#, β 0.201; Q3#, β 0.248, Q4#, β 0.370]. UA level was negatively associated with GS in female in the Q4 group [β -0.039, 95% CI -0.070-0.008]. Besides, the serum UA levels showed an inverted J-shaped relationship with HGS in female [Q2#, β 0.737; Q3#, β 1.142, Q4#, β 0.694]. While in male, the UA levels was significantly associated with SMI in Q3 and Q4 group [Q3#, β 0.237, Q4#, β 0.359]. And UA levels was only associated with HGS in the Q4 group in male [β 1.406, 95% CI 0.018-2.794].

**Discussion**

Our study investigated the relationship between UA levels and sarcopenia or its three components in a large sample of community of West China using AWGS 2019 diagnostic algorithm. We showed that serum UA levels shared a significant inverted J-shaped curve relationship with HGS in female and only a positive relationship in male in Q4 group after adjustment for potential confounding factors. This was consistent with previous studies. One study showed that an inverted J-shaped association between serum UA levels and HGS in both genders among Chinese adults aged over 45. Another study in China showed that higher uric acid levels were significantly correlated with higher muscle mass, grip strength in 388 participants aged over 60. Besides, study in Japan found an inverted J-shaped association
between the serum UA quartiles and muscle strength in 630 male Japanese employees aged over 30 years old. Moreover, a most recent prospective cohort study reported that a higher baseline UA levels still remained significantly associated with higher follow-up strength measures during a 3-year follow-up period. These studies supported that maintaining optimal levels of serum UA may help to maintain the quality and strength of skeletal muscle. The mechanism might be related with the powerful antioxidant capacity of UA which may protect skeletal muscle function from ROS-induced protein oxidative damage. Besides, low UA level might be a marker of low nutrient status, which was an important risk factor associated with poor grip strength. Moreover, elevated serum UA levels were positively correlated with serum creatinine level which was correlated to the individual's muscle mass. However, it was well known that an increased UA level was related to high inflammatory cytokines such as IL-6, CRP and TNF-α, which were contributors to poor muscle strength. Besides, the gender difference of the relationship between UA and HGS in our study could be related with hormone difference. Several studies reported that estrogen promotes UA secretion and leads to increases in UA levels in postmenopausal women, which may partially strengthen the significant association between UA and ASM in the total female population.

In our study, we found that UA level was also significantly associated with SMI, irrespective of gender. This implying that higher UA maybe protective in maintaining muscle mass. Consistently, another study also found that UA was positively associated with ASM in a retrospective cohort. Interestingly, this association was only significant in males but not in females. Another cross-sectional study in China which included 3,079 middle-aged and older participants indicated a positive association between UA and ASMI which was tested by dual-energy X-ray absorptiometry. Besides, in men with T2DM, higher serum UA was found to be an independent risk factor of reduced muscle mass. In hemodialysis (HD) patients, UA was identified as a nutritional marker and was shown to be positively associated with nutritional markers. The mechanism could also be explained. Firstly, higher UA levels was found to be positively associated with the rate of normalized protein equivalent of nitrogen appearance, which was shown to be beneficial for skeletal muscle mass. Secondly, extracellular UA has antioxidant effects, acting as a powerful scavenger of free radicals, protecting muscle cell from oxidative damage. Thirdly, UA was shown to have potential therapeutic effects in suppressing the redox process, promoting both myoblast proliferation and differentiation in muscle aging.

However, in our study, UA was found significantly associated with gait speed only in female in the highest group. While higher UA was found to be related with lower gait speed. This was also consistent with previous studies. One previous study showed that serum UA were associated with low physical activity (OR 1.10, 95%CI 0.99-1.23), also associated with low walking speed (OR 1.08, 95%CI 0.95-1.23). Conversely, higher UA level was found to have no relationship with physical performance which was assessed using Short Physical Performance Battery (SPPB) scale in another two cross-sectional study. This might be explained by the reason that SPPB is a final sum of multiple parameters that included walking speed over 4 meters, five timed repeated chair rises and standing balance. That is why
SPPB was affected not only by muscle strength but also by balance and coordination. Anyway, the relationship between UA and gait speed need to be further investigated.

Towards the prevalence of sarcopenia, UA was found to be significantly associated sarcopenia both in female and male in our study after adjusted confounding factors and it seemed that higher UA was a protective factor. However, a previous research found that elevations in UA may lead to sarcopenia and they thought that UA could lead to reactive oxygen species formation and inflammation, both of which are associated with sarcopenia\(^9\). And another research found that sarcopenia might be treated using allopurinol, a medicine which could reduce the serum UA level\(^30\). On the contrary, as our previous discussed, serum UA may have a protective role in aging-associated decline in muscle strength as UA has strong anti-oxidant properties\(^31\). Since our study included most relatively “healthy” participants, the level of UA was not very much high. The antioxidant effect was not overwhelmed by its harmful inflammatory effect and might be related with slowing down the progress of sarcopenia.

**Conclusions**

In conclusion, our findings showed an independent association of higher UA serum levels with sarcopenia in west China and UA was significantly associated with HGS/SMI, not with GS. Besides, there were not much distinct difference when these relationships were studied in men and women separately. This indicated that maintaining a specific higher concentration of UA could have some important biological advantage. Specifically, UA plays a role in the antioxidant ability on muscle proteins and slows down the progression of sarcopenia among older persons.

**Limitations**

Some limitations of our study need to be considered. Firstly, people over 50 years old were enrolled in this study and most of them were in the age range of 50-60 years old. The relationship between UA level and sarcopenia could only reflect mostly middle aged participants. Secondly, although we included many important confounders in our study. More adjustment should be made for confounders. For example, gout and medicine intake which might affect the UA level should be adjusted. Besides, we used 4 meter gait speed evaluation instead of 6 meter gait speed and this might exist some bias. Lastly, our study was an observational cross-sectional study which cannot determine the causal relationship between sarcopenia and serum UA level.

**Declarations**

**Availability of Data and Materials**
The datasets generated and analyzed during the current study will be available two years later and is also available now from the corresponding author on a reasonable request.

**Acknowledgement**

We thank all the volunteers for the participation and personnel for their contribution in the WCHAT study.

**Ethics approval and consent to participate**

Subjects (or their guardians) have given their written informed consent. The current research was approved by the Ethical Review Committee of West China Hospital with the committee's reference number 2017(445) and the registration number is ChiCTR 1800018895. All methods were performed in accordance with the relevant guidelines and regulations.

**Declarations of interest**

None.

**Funding Sources**

This work was funded by National Clinical Research Center for Geriatric (Z2018B09), the Fundamental Research Funds for the Central University (20826041D4046), Post-doc Coronavirus Epidemic Prevention and Control Fund (0040204153349), West China Hospital Postdoctoral Fund (2020HXBH011), National Key R&D Program of China (2017YFC0840100 and 2017YFC0840101) and National Key R&D Program of China (2020YFC2005600 and 2020YFC2005602).

**Author Contributions**

Xiaolei Liu and Xiaoyan Chen design and write the manuscript. Lisha Hou and Xin Xia helped analyzed data. Fengjuan Hu, Shuyue Luo, Gongchang Zhang, Xuelian Sun and Xuchao Peng helped collect data. Jirong Yue and Birong Dong helped revise the manuscript.

**Consent for publication**

Not applicable.

**References**

1. Rosenberg IH. Sarcopenia: origins and clinical relevance. *The Journal of nutrition*. May 1997;127(5 Suppl):990s-991s.

2. Liu X, Hou L, Xia X, et al. Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment: findings from West-China health and aging trend study. Feb 17 2020;20(1):63.
3. Marzetti E, Calvani R, Tosato M, et al. Sarcopenia: an overview. Aging clinical and experimental research. Feb 2017;29(1):11-17.

4. Liu X, Hao Q, Yue J, et al. Sarcopenia, Obesity and Sarcopenia Obesity in Comparison: Prevalence, Metabolic Profile, and Key Differences: Results from WCHAT Study. The journal of nutrition, health & aging. 2020/02/12 2020.

5. Xu L, Jing Y, Zhao C, et al. Cross-sectional analysis of the association between serum uric acid levels and handgrip strength among Chinese adults over 45 years of age. Annals of translational medicine. Dec 2020;8(23):1562.

6. Floriano JP, Nahas PC, de Branco FMS, Dos Reis AS. Serum Uric Acid Is Positively Associated with Muscle Mass and Strength, but Not with Functional Capacity, in Kidney Transplant Patients. Aug 10 2020;12(8).

7. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. The Journal of physiology. Mar 16 2004;555(Pt 3):589-606.

8. Huang C, Niu K, Kobayashi Y, et al. An inverted J-shaped association of serum uric acid with muscle strength among Japanese adult men: a cross-sectional study. BMC musculoskeletal disorders. Aug 30 2013;14:258.

9. Beavers KM, Beavers DP, Serra MC, Bowden RG, Wilson RL. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: findings from NHANES III. The journal of nutrition, health & aging. Mar 2009;13(3):177-182.

10. Hou L, Liu X, Zhang Y, et al. Cohort Profile: West China Health and Aging Trend (WCHAT). Journal Of Nutrition Health & Aging. 2020.

11. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. Mar 2020;21(3):300-307.e302.

12. Liu X, Hou L, Zhao W, et al. The Comparison of Sarcopenia Diagnostic Criteria using AWGS 2019 with the Other Five Criteria in West China. Gerontology. Feb 17 2021:1-11.

13. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Journal of the American Geriatrics Society. Oct 1975;23(10):433-441.

14. Lim PP, Ng LL, Chiam PC, Ong PS, Ngui FT, Sahadevan S. Validation and comparison of three brief depression scales in an elderly Chinese population. International journal of geriatric psychiatry. Sep 2000;15(9):824-830.
15. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry research.* May 1989;28(2):193-213.

16. Xu ZR, Zhang Q, Chen LF, et al. Characteristics of hyperuricemia in older adults in China and possible associations with sarcopenia. Jun 2018;1(1):23-34.

17. Macchi C, Molino-Lova R, Polcaro P, et al. Higher circulating levels of uric acid are prospectively associated with better muscle function in older persons. *Mechanisms of ageing and development.* Sep 2008;129(9):522-527.

18. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. *Physiology (Bethesda, Md.).* Apr 2005;20:125-133.

19. Norman K, Schütz T, Kemps M, Josef Lübke H, Lochs H, Pirlich M. The Subjective Global Assessment reliably identifies malnutrition-related muscle dysfunction. *Clinical nutrition (Edinburgh, Scotland).* Feb 2005;24(1):143-150.

20. Kurahashi H, Watanabe M, Sugimoto M, et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. *Endocrine journal.* 2013;60(12):1321-1327.

21. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. *PLoS One.* 2011;6(5):e19901.

22. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey. *Arthritis research & therapy.* 2008;10(5):R116.

23. Xiao X, Yi C, Peng Y, et al. The Association between Serum Uric Acid and Appendicular Skeletal Muscle Mass and the Effect of Their Interaction on Mortality in Patients on Peritoneal Dialysis. *Kidney & blood pressure research.* 2020;45(6):969-981.

24. Dong XW, Tian HY, He J, Wang C, Qiu R, Chen YM. Elevated Serum Uric Acid Is Associated with Greater Bone Mineral Density and Skeletal Muscle Mass in Middle-Aged and Older Adults. *PLoS One.* 2016;11(5):e0154692.

25. Tanaka KI, Kanazawa I, Notsu M, Sugimoto T. Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.* Jan 2021;129(1):50-55.

26. Beberashvili I, Sinuani I, Azar A, et al. Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients. *Nutrition (Burbank, Los Angeles County,*
27. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proceedings of the National Academy of Sciences of the United States of America*. Nov 1981;78(11):6858-6862.

28. Derbré F, Gratas-Delamarche A, Gómez-Cabrera MC, Viña J. Inactivity-induced oxidative stress: a central role in age-related sarcopenia? *European journal of sport science*. 2014;14 Suppl 1:S98-108.

29. García-Esquinas E, Guallar-Castillón P, Carnicero JA, et al. Serum uric acid concentrations and risk of frailty in older adults. *Experimental gerontology*. Sep 2016;82:160-165.

30. Ferrando B, Olaso-Gonzalez G, Sebastia V, Viosca E, Gomez-Cabrera MC, Viña J. [Allopurinol and its role in the treatment of sarcopenia]. *Revista espanola de geriatria y gerontologia*. Nov-Dec 2014;49(6):292-298.

31. Kawamoto R, Ninomiya D, Kasai Y, et al. Serum Uric Acid Is Positively Associated with Handgrip Strength among Japanese Community-Dwelling Elderly Women. *PLoS One*. 2016;11(4):e0151044.

**Tables**

Table 1. Baseline characteristics of participants according to the quartiles of UA.
| Characteristics               | Uric Acid tertiles (umol/L)                  |   |   |   | P    |
|------------------------------|---------------------------------------------|---|---|---|------|
|                              | Q1(n=1065)                                  | Q2(n=1065) | Q3(n=1065) | Q4(n=1065) |
| Age (years), mean (SD)       | <269.825                                    | 269.825~318.15 | 318.15~378.75 | ≥378.75 | 0.01 |
| Female (%)                   | 953(89.48)                                  | 801(75.21)   | 621(58.31)   | 343(32.21) | 0.01 |
| Ethnic groups (%)            | 0.018                                       |             |             |           |      |
| Han                          | 433(40.66)                                  | 465(43.66)   | 480(45.07)   | 461(43.29) |
| Zang                         | 292(27.42)                                  | 283(26.57)   | 299(28.08)   | 330(30.99) |
| Qiang                        | 286(26.85)                                  | 272(25.54)   | 229(21.5)    | 222(20.85) |
| Yi                           | 54(5.07)                                    | 45(4.23)     | 57(5.35)     | 52(4.87)    |
| Education (%)                | 0.01                                        |             |             |           |      |
| No formal education          | 395(39.42)                                  | 301(29.6)    | 295(29.27)   | 255(25.05)  |
| Primary school               | 314(31.34)                                  | 367(36.09)   | 325(32.24)   | 360(35.36)  |
| Middle school and above      | 293(29.24)                                  | 349(34.32)   | 388(39.49)   | 403(39.59)  |
| smoking history (%)          | 0.01                                        |             |             |           |      |
| No                           | 936(93.69)                                  | 887(87.82)   | 793(79.06)   | 700(68.97)  |
| Yes                          | 63(6.31)                                    | 123(12.18)   | 210(20.94)   | 315(31.03)  |
| drinking history (%)         | 0.01                                        |             |             |           |      |
| No                           | 838(83.88)                                  | 805(79.7)    | 743(74.08)   | 627(61.77)  |
| Yes                          | 161(16.12)                                  | 205(20.3)    | 260(25.92)   | 388(38.23)  |
| ADL score, mean (SD)         | 99.18(3.51)                                 | 99.11(3.50)  | 99.07(3.82)  | 99.01(3.36) |
| GDS score, mean (SD)         | 2.85(2.43)                                  | 2.68(2.35)   | 2.57(2.42)   | 2.49(2.23)  |
| Cognitive function (%)       | 0.01                                        |             |             |           |      |
| No decline                   | 820(82.16)                                  | 878(87.02)   | 851(85.01)   | 911(89.93)  |

Page 13/19
|                      | Mild decline | Moderate-severe decline | Sleep quality (%) | Hypertension (%) | Diabetes (%) | CHD | Liver disease (%) | Gastrointestinal disease (%) | Stoke history (%) | COPD (%) | Osteoarticular disease(%) |
|----------------------|--------------|-------------------------|-------------------|------------------|-------------|-----|------------------|-----------------------------|------------------|----------|--------------------------|
|                      | 126(52)      | 107(10.6)               | 113(11.29)        | 77(7.6)          |             |     |                  |                             |                  |          |                          |
| Sleep quality (%)    |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| Good                 | 529(52.53)   | 539(53.05)              | 517(51.19)        | 542(53.88)       |             |     |                  |                             |                  |          |                          |
| Bad                  | 478(47.47)   | 477(46.95)              | 493(48.81)        | 464(46.12)       |             |     |                  |                             |                  |          |                          |
| Good                 |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| Bad                  |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| Hypertension (%)     |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 881(82.72)^cd| 858(80.56)^d           | 814(76.43)^ad     | 721(67.7)^abc    |             |     |                  |                             |                  |          |                          |
| Yes                  | 184(17.28)   | 207(19.44)              | 251(23.57)        | 344(32.3)        |             |     |                  |                             |                  |          |                          |
| Diabetes (%)         |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 1006(94.46)^d| 1000(93.9)^d           | 1000(93.9)^d      | 102(9.58)^abc    |             |     |                  |                             |                  |          |                          |
| Yes                  | 59(5.54)     | 65(6.1)                 | 65(6.1)           | 963(90.42)       |             |     |                  |                             |                  |          |                          |
| CHD                  |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 1042(97.84)^d| 1039(97.56)             | 1038(97.46)       | 1020(95.77)^a    |             |     |                  |                             |                  |          |                          |
| Yes                  | 23(2.16)     | 26(2.44)                | 27(2.54)          | 45(4.23)         |             |     |                  |                             |                  |          |                          |
| Liver disease (%)    |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 1045(98.12)  | 1040(97.65)             | 1043(2.07)        | 1032(96.9)       |             |     |                  |                             |                  |          |                          |
| Yes                  | 20(1.88)     | 25(2.35)                | 22(97.93)         | 33(3.1)          |             |     |                  |                             |                  |          |                          |
| Gastrointestinal disease (%) |         |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 984(92.39)   | 1005(94.37)             | 1005(94.37)       | 1008(94.65)      |             |     |                  |                             |                  |          |                          |
| Yes                  | 81(7.61)     | 60(5.63)                | 60(5.63)          | 57(5.35)         |             |     |                  |                             |                  |          |                          |
| Stoke history (%)    |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 1046(98.22)  | 1054(98.97)             | 1051(98.69)       | 1043(97.93)      |             |     |                  |                             |                  |          |                          |
| Yes                  | 19(1.78)     | 11(1.03)                | 14(1.31)          | 22(2.07)         |             |     |                  |                             |                  |          |                          |
| COPD (%)             |              |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No                   | 1059(99.44)^c| 1056(99.15)             | 1045(98.12)^a     | 1054(98.97)      |             |     |                  |                             |                  |          |                          |
| Yes                  | 6(0.56)      | 9(0.85)                 | 20(1.88)          | 11(1.03)         |             |     |                  |                             |                  |          |                          |
| Osteoarticular disease (%) |          |                         |                   |                  |             |     |                  |                             |                  |          |                          |
| No   | 960(90.14)\(^b\) | 996(93.52)\(^a\) | 984(92.39) | 976(91.64) |
|------|------------------|------------------|------------|------------|
| Yes  | 105(9.86)        | 69(6.48)         | 81(7.61)   | 89(8.36)   |

**Note:** Baseline characteristics of participants according to the quartiles of UA. For continuous variables, one-way ANOVA was used to detect differences across groups for the continuous variables, and Fisher's Least Significant Difference (LSD) post hoc analysis was used to determine the difference between every two groups. For the categorical variables, the chi-squared test was used to detect the difference across groups. When significant difference was identified across groups, column proportions tests (z-tests) with Bonferroni correction were performed to determine the difference between every two groups. During most testing, \(p<0.05\) was considered statistically significant, however, \(p\)-values were corrected for z-tests with the Bonferroni correction (with the statistical significance set at \(p<0.008\), where \(0.008=0.05/6\)). \(Q\) stands for UA: \(Q1\) is the lowest quartile and \(Q4\) is the highest quartile. \(^a\) Significantly different from the \(Q1\) group. \(^b\) Significantly different from the \(Q2\) group. \(^c\) Significantly different from the \(Q3\) group. \(^d\) Significantly different from the \(Q4\) group. CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.

Table 2. The relationship between UA tertiles and sarcopenia in non-adjusted model and adjusted model.

| variable | Non-adjusted Model | Adjusted Model |
|----------|-------------------|----------------|
|          | \(P\)-value | OR (95% CI) | \(P\)-value | OR (95% CI) |
| Male     |                |              |              |              |
| Q1\(^*\) | -            | -            | -            | -            |
| Q2\(^*\) | 0.248        | 0.836(0.618-1.133) | 0.572 | 0.903(0.633-1.288) |
| Q3\(^*\) | 0.004        | 0.629(0.459-0.861) | 0.027 | 0.664(0.462-0.955) |
| Q4\(^*\) | \(\leq0.001\) | 0.442(0.317-0.616) | 0.001 | 0.513(0.349-0.753) |
| Female   |                |              |              |              |
| Q1\(^#\) | -            | -            | -            | -            |
| Q2\(^#\) | 0.002        | 0.666(0.514-0.864) | 0.037 | 0.729(0.542-0.982) |
| Q3\(^#\) | 0.001        | 0.653(0.504-0.848) | 0.001 | 0.593(0.436-0.805) |
| Q4\(^#\) | 0.001        | 0.645(0.497-0.837) | \(\leq0.001\) | 0.477(0.348-0.652) |

**Note:** Adjusted model: adjusted age, ethnic groups, GDS score, sleeping quality, education level, cognitive function, smoking history, drinking history, ADL score, and chronic diseases (hypertension, diabetes, coronary heart disease, chronic obstructive pulmonary disease, osteoarthropathy, liver disease, gastrointestinal disease, stroke history). In female: \(Q1\)^\#(253.85umol/l, 253.85umol/l \(\leq Q2\)^\#(293.8umol/l, 293.8umol/l \(\leq Q3\)^\#(340.4umol/l, 340.4umol/l \(\leq Q4\)^\#); In male: \(Q1\)^*\#(319.2umol/l, 319.2umol/l \(\leq Q2\)^*\#(372.25umol/l, 372.25umol/l \(\leq Q3\)^*\#(423.525umol/l, 423.525umol/l \(\leq Q4\)^*.
Table 3. General linear model testing the relationship between UA tertiles and SMI, gait speed, handgrip strength after adjusting for relevant confounders.
| variable          | β   | SE  | P-value | 95%CI  |
|-------------------|-----|-----|---------|--------|
| **In female**     |     |     |         |        |
| SMI               |     |     |         |        |
| Q1# (Ref)         | -   | -   | -       | -      |
| Q2#               | 0.201 | 0.0418 | <0.001 | 0.119  | 0.283  |
| Q3#               | 0.248 | 0.0415 | <0.001 | 0.167  | 0.33   |
| Q4#               | 0.27  | 0.0417 | <0.001 | 0.189  | 0.352  |
| Gait speed (GS)   |     |     |         |        |
| Q1# (Ref)         | -   | -   | -       | -      |
| Q2#               | 0.004 | 0.0156 | 0.817  | -0.027 | 0.034  |
| Q3#               | 0.01  | 0.0155 | 0.512  | -0.02  | 0.041  |
| Q4#               | -0.039 | 0.0156 | 0.012  | -0.07  | -0.008 |
| Handgrip strength (HGS) | | | |
| Q1# (Ref)         | -   | -   | -       | -      |
| Q2#               | 0.737 | 0.3212 | 0.022  | 0.107  | 1.366  |
| Q3#               | 1.142 | 0.3194 | <0.001 | 0.516  | 1.768  |
| Q4#               | 0.694 | 0.3207 | 0.03   | 0.066  | 1.323  |
| **In male**       |     |     |         |        |
| SMI               |     |     |         |        |
| Q1# (Ref)         | -   | -   | -       | -      |
| Q2#               | 0.088 | 0.0599 | 0.144  | -0.03  | 0.207  |
| Q3#               | 0.237 | 0.0598 | <0.001 | 0.12   | 0.354  |
| Q4#               | 0.359 | 0.0605 | <0.001 | 0.241  | 0.476  |
| Gait speed (GS)   |     |     |         |        |
| Q1# (Ref)         | -   | -   | -       | -      |
| Q2#               | 0.01  | 0.0205 | 0.642  | -0.031 | 0.05   |
| Q3#               | 0.005 | 0.0203 | 0.821  | -0.035 | 0.044  |
|       | Q4* | 0.006 | 0.0203 | 0.757 | -0.034 | 0.046 |
|-------|-----|--------|--------|-------|--------|-------|
| **Handgrip strength (HGS)** |     |        |        |       |        |       |
| Q1*(Ref) | -   | -      | -      | -     | -      | -     |
| Q2*    | 0.233 | 0.7151 | 0.745  | -1.169 | 1.635  |
| Q3*    | 0.482 | 0.7068 | 0.495  | -0.903 | 1.867  |
| Q4*    | 1.406 | 0.7083 | 0.047  | 0.018  | 2.794  |

**Note:** General linear model was adjusted age, ethnic groups, GDS score, sleeping quality, education level, cognitive function, smoking history, drinking history, ADL score, and chronic disease (hypertension, diabetes, coronary heart disease, chronic obstructive pulmonary disease, osteoarthritis, liver disease, gastrointestinal disease, stroke history). In female: Q1* ≤ 253.85umol/l, 253.85umol/l ≤ Q2* ≤ 293.8umol/l, 293.8umol/l ≤ Q3* ≤ 340.4umol/l, 340.4umol/l ≤ Q4*; In male: Q1* ≤ 319.2umol/l, 319.2umol/l ≤ Q2* ≤ 372.25umol/l, 372.25umol/l ≤ Q3* ≤ 423.525umol/l, 423.525umol/l ≤ Q4*.

**Figures**

**Figure 1**
Flow chart of study participants. Initially, we recruited 7536 community-dwelling multi-ethnic residents in total. 4500 participants did the bioelectrical impedance analysis (BIA) which is available for the selection of sarcopenia. Then other small ethnic group participants (n=67), participants without blood uric acid test (n=57), participants with kidney disease (n=87), participants with mental disease (n=5) and participants with tumor (n=24) were excluded. Finally, 4260 participants were included and were grouped according to UA quartiles in our study.